Navigation Links
Cancer drugs in the pipeline
Date:12/11/2008

SAN ANTONIO - Scientists in the clinic and the laboratory continue to work to drive breast cancer mortality rates down with breakthrough drugs. With tamoxifen's discovery 30 years behind us, and the impact of Herceptin still being felt, researchers are studying zoledronic acid, aromatase inhibitors and monoclonal antibodies, among others, with encouraging results. Data will be presented at the CTRC-AACR San Antonio Breast Cancer Symposium.


Zoledronic Acid May Have Anti-Tumor Properties
Abstract #5101, Robert Coleman, M.D

Early results of the AZURE (Adjuvant Zoledronic Acid to Reduce Recurrence) trial suggest that zoledronic acid may have antitumor properties when combined with chemotherapy. Treatment was linked with a reduction in tumor size (20.5 mm vs. 30 mm), an increase in the complete response rate (10.9 percent vs. 5.8 percent) and a decrease in the number of patients requiring mastectomy (65.3 percent vs. 77.9 percent).

Full release available/Complete data to be presented at the meeting.


Breast Cancer Patients May have Better Option to Reduce Estrogen Levels
Abstract #15, Stephen Jones, M.D
Embargo: 10:15 a.m. CST, December 11, 2008

Despite adjuvant therapy to reduce estrogen levels, one in five breast cancer survivors will have a recurrence. The first results from the TEAM study, one of the largest clinical trials ever conducted for invasive breast cancer, demonstrated that exemestane may be more effective in postmenopausal women than current treatment with tamoxifen. Exemestane is an agent that actually stops the body from producing estrogen.

Full data to be presented at the meeting.


Herceptin Increases Event-Free Survival in Locally Advanced HER2-Postive Breast Cancer
Abstract #31, Luca Gianni, M.D

Among patients with HER2-positive, locally advanced breast cancer, neoadjuvant treatment with Herceptin increased three-year, event-free survival to 70 percent compared with 53 percent among those receiving chemotherapy alone. The addition of trastuzumab (Herceptin) was well tolerated with acceptable cardiac safety. Researchers claim this phase III clinical trial establishes chemotherapy with one year of Herceptin as a standard treatment option in this patient population.

Full data to be presented at the meeting.


Lapatinib Improved Progression-Free Survival in Postmenopausal Women with Breast Cancer
Abstract #46, Stephen Johnston, Ph.D

For the treatment of women with hormone-receptor-positive metastatic breast cancer that also co-expressed HER2, combining lapatinib with an aromatase inhibitor significantly improved progression-free survival from three months in the letrozole alone group to 8.2 months in the combination group. Overall clinical benefit rate increased from 28.7 percent to 48.7 percent. Involving 1,286 patients, this is the largest trial of its kind to date.

Full data to be presented at the meeting.


Adjuvant Aromatase Inhibitors Lower Breast Cancer Recurrence Risk
Abstract #12, James Ingle, M.D.
Embargo: 9:30 a.m. CST, December 11, 2008

Adjuvant therapy with aromatase inhibitors (AIs) for postmenopausal estrogen-receptor-positive breast cancer given either as initial monotherapy or after several years of tamoxifen decreases the risk of recurrent disease more than tamoxifen, according to two meta-analyses. The risk reduction with AIs was statistically significant.

Full data to be presented at the meeting.


'/>"/>

Contact: Jeremy Moore
Jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer
2. Pilots May Face Greater Cancer Risk
3. Estrogen pills can benefit women with metastatic breast cancer
4. Light shines for potential early cancer diagnosis technique
5. LegalView Reports That Skin Cancer Drug May Offer Treatment to Mesothelioma Patients
6. PADRES Contra El Cancer to Host its 10th Annual Posada Holiday Celebration for Children with Cancer
7. UBC researchers discover gene mutation that causes eye cancer
8. Treadmill Desks More Effective in Decreasing Prostate Cancer Risks Than Vitamin and Antioxidant Supplements
9. Hormone therapy for prostate cancer does not appear to increase cardiac deaths
10. Oral cancer patients could be diagnosed earlier
11. PreMD Files Provisional Patent Application Describing a New Method of Quantifying Cancer Biomarkers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 26, 2016 Story Highlights: ... models within the health care industry is causing providers ... , Deloitte offers a suite of solutions for ... impacting efficient cost optimization: labor resource analysis, revenue cycle ... facilitate better outcomes and better economics ...
(Date:6/24/2016)... CAMBRIDGE, Mass. , June 24, 2016 /PRNewswire/ ... the Spaulding Rehabilitation Network,s Dean Center for ... of Physical Medicine and Rehabilitation, MIT Hacking Medicine, ... Center for Innovation, today announced the five finalists ... Hackathon for Lyme disease.  More than 100 scientists, ...
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
Breaking Medicine Technology: